Immatics

Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

Biotech

Equities

News

Health Care

Financing

Offerings

Movers

Trading Ideas

General

IMTX

Immatics announced updated Phase 1b data for its IMA203 therapy in metastatic melanoma. A deep tumor reduction response was observed in about half of the patients, with positive survival benefits shown. Phase 3 trials are set to begin by December 2024.

Why Is Cancer-Focused Immatics Stock Trading Lower On Thursday?

Earnings

Earnings Beats

Large Cap

Small Cap

Management

Markets

Analyst Ratings

TRDA

AstraZeneca (NASDAQ: AZN) announced that the combination therapy of its PD-L1 inhibitor, Imfinzi (durvalumab), and PARP inhibitor, Lynparza (olaparib), has been approved in the EU to treat certain patients with primary advanced or recurrent endometrial cancer, also known as uterine cancer.

AstraZeneca Imfinzi Combo Gets EU Nod for Uterine Cancer

Earnings Misses

HALO

UTHR

United Therapeutics‘ (NASDAQ: UTHR) second-quarter 2024 earnings of $5.85 per share missed the Zacks Consensus Estimate of $6.33. Earnings rose 12% year over year on the back of higher product sales.

United Therapeutics Q2 Earnings Lag, Sales Top Estimates

Immatics NV

Press Releases

Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024

Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial

Immatics Announces Proposed $150 Million Public Offering

Immatics Announces Pricing of $150 Million Public Offering

Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME

Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME

Clear Street Launches Healthcare & Biotechnology Equity Research

Immatics Announces Full Year 2024 Financial Results and Business Update

Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting

Immatics Announces First Quarter 2025 Financial Results and Business Update

CGEM

CRGX

DCTH

ELVN

ERAS

IPSC

JANX

MLTX

NUVB

PTGX

YMAB

Akebia Therapeutics

AnaptysBio

ArriVent BioPharma

Anavex Life Sciences Corp. - Common Stock

Anavex Life Sciences

Bicara Therapeutics

Bicycle Therapeutics plc - American Depositary Shares

Bicycle Therapeutics

Cogent Biosciences

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

Dianthus Therapeutics, Inc. - Common Stock

Dianthus Therapeutics

Geron

Immunome

Iovance Biotherapeutics, Inc. - Common Stock

Iovance Biotherapeutics

KalVista Pharmaceuticals, Inc. - Common Stock

KalVista Pharma

Keros Therapeutics

Nurix Therapeutics

Pharming Group N.V. - ADS, each representing 10 ordinary shares

Pharming

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicine

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals

Replimune Group

Regulus Therapeutics

Sionna Therapeutics

Taysha Gene Therapies, Inc. - Common Stock

Taysha Gene Therapies

Vir Biotechnology

Xencor

Zymeworks

B of A Securities

Piper Sandler

Mizuho

Chardan Capital

SVB Leerink

Comments

Immatics

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell